Seres Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference · Filed/ | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Description | Form | File No. | Exhibit | FilingDate | FurnishedHerewith |
| 2.11†† | Asset Purchase Agreement, dated August 5, 2024, by and between Seres Therapeutics, Inc. and Société des Produits Nestlé S.A. | 8-K | 001-37465 | 2.1 | 8/6/24 | |
| 3.1 | Restated Certificate of Incorporation, filed on July 1, 2015 | 8-K | 001-37465 | 3.1 | 7/1/15 | |
| 3.2 | Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated June 27, 2023 | 8-K | 001-37465 | 3.1 | 6/28/23 | |
| 3.3 | Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated April 5, 2024 | 8-K | 001-37465 | 3.1 | 4/8/24 | |
| 3.4 | Amended and Restated Bylaws | 8-K | 001-37465 | 3.1 | 1/2/24 | |
| 10.1 | Securities Purchase Agreement, dated September 30, 2024, by and between Seres Therapeutics, Inc. and Société des Produits Nestlé S.A. | 8-K | 001-37465 | 10.1 | 10/1/24 | |
| 10.2† | Transition Services Agreement, dated September 30, 2024, by and between Seres Therapeutics, Inc. and Nestlé Enterprises S.A. | 8-K | 001-37465 | 10.2 | 10/1/24 | |
| 10.3 | Cross-License Agreement, dated September 30, 2024, by and between Seres Therapeutics, Inc. and Société des Produits Nestlé S.A. | 8-K | 001-37465 | 10.3 | 10/1/24 | |
| 10.4 | Employee Support Agreement, dated September 30, 2024, by and between Seres Therapeutics, Inc. and Société des Produits Nestlé S.A. | 8-K | 001-37465 | 10.4 | 10/1/24 | |
| 10.5† | Assignment and Termination of Manufacturing Agreement, dated August 5, 2024, by and between Seres Therapeutics, Inc. and Bacthera AG | 10-Q | 001-37465 | 10.5 | 8/13/24 | |
| 10.6 | Mutual Termination of License Agreement dated September 30, 2024, by and between Seres Therapeutics, Inc. and NHSc Rx License GmbH | * | ||||
| 10.7 | Mutual Termination of Collaboration and License Agreement dated September 30, 2024, by and between Seres Therapeutics, Inc. and Société des Produits Nestlé S.A. | * | ||||
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer | * | ||||
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer | * | ||||
| 32.1 | Section 1350 Certification of Chief Executive Officer | ** | ||||
| 32.2 | Section 1350 Certification of Chief Financial Officer | ** | ||||
| 101.INS | Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document | * | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | * | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | * | ||||
- Filed herewith.
** Furnished herewith.
† Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Regulation S-K, Item 601(b)(10)(iv). Such omitted information is both (i) not material and (ii) the type that the Registrant treats as private or confidential.
†† Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.